Tekla Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Tekla Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.27M	Sell	22,571 -32,509	-59%	-$1.84M	0.05%	125
2023 Q1	$2.49M	Hold	55,080	–	–	0.09%	113
2022 Q4	$2.24M	Hold	55,080	–	–	0.08%	109
2022 Q3	$3.6M	Hold	55,080	–	–	0.15%	94
2022 Q2	$3.35M	Hold	55,080	–	–	0.13%	99
2022 Q1	$3.46M	Hold	55,080	–	–	0.12%	105
2021 Q4	$4.17M	Sell	55,080 -107,257	-66%	-$9.37M	0.13%	106
2021 Q3	$18.2M	Hold	162,337	–	–	0.59%	50
2021 Q2	$26.3M	Buy	162,337 +11,379	+8%	+$1.38M	0.85%	28
2021 Q1	$18.4M	Buy	150,958 +74,736	+98%	+$11.3M	0.63%	42
2020 Q4	$11.7M	Hold	76,222	–	–	0.41%	71
2020 Q3	$6.38M	Hold	76,222	–	–	0.24%	93
2020 Q2	$5.6M	Hold	76,222	–	–	0.21%	94
2020 Q1	$3.23M	Hold	76,222	–	–	0.15%	110
2019 Q4	$4.64M	Sell	76,222 -25,114	-25%	-$1.37M	0.18%	109
2019 Q3	$4.15M	Sell	101,336 -77,012	-43%	-$3.68M	0.18%	94
2019 Q2	$8.4M	Hold	178,348	–	–	0.34%	67
2019 Q1	$6.37M	Hold	178,348	–	–	0.26%	81
2018 Q4	$5.09M	Hold	178,348	–	–	0.22%	86
2018 Q3	$7.91M	Hold	178,348	–	–	0.29%	76
2018 Q2	$10.5M	Buy	178,348 +37,157	+26%	+$2.12M	0.4%	58
2018 Q1	$6.45M	Buy	+141,191	New	+$5.83M	0.25%	84

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tekla Capital Management's CRSP Position: Q2 2023 in Review

Tekla Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 59% in Q2 2023, selling an estimated $1.84M and leaving 22,571 shares worth $1.27M. The position accounts for 0.05% of the portfolio, ranked #125.

Tekla Capital Management first reported a position in CRSP in Q1 2018 and has held it in 22 quarters since. The position peaked at $26.3M in Q2 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Tekla Capital Management held 22,571 shares of CRISPR Therapeutics worth $1.27M as of Q2 2023.
Tekla Capital Management sold 32,509 CRISPR Therapeutics shares in Q2 2023, an estimated $1.84M.
CRISPR Therapeutics made up 0.05% of Tekla Capital Management's portfolio in Q2 2023, its #125 holding.
Tekla Capital Management first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 22 quarters since.
Tekla Capital Management's CRISPR Therapeutics position peaked at $26.3M in Q2 2021.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.